EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice

Jian Zhou, Yuan Yuan, Yanhua Liu, Mengyang Chu, Huan Liu, Qian Liu, Rui Wang, Shuai Shao, Gang Wang, Chen Yu iD

Experimental Dermatology · 2024

DOI: 10.1111/exd.14890 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Experimental Dermatology, 2024. Verfasst von Jian Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, P. R. China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Psoriasis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A number of randomized controlled trials and real‐world studies have demonstrated the effectiveness and safety of secukinumab in the treatment of moderate to severe psoriasis, whereas data on a large cohort of Chinese patients in long‐term real‐world practice are limited. This was a single‐centre, uncontrolled, single‐arm, prospective, observational cohort study that included 254 psoriatic patients treated with secukinumab between September 2019 and December 2022. Demographic and clinical characteristics of patients, clinical response and adverse events were evaluated. The 75% improvement in Psoriasis Area and Severity Index score (PASI 75), PASI 90, and PASI 100 in the 300 mg secukinumab group at 12 weeks were 91.7%, 74.0% and 39.7% respectively, increasing to 94.5%, 74.5% and 47.6% at 52 weeks. High body mass index (BMI), previous exposure to biologic therapies and history of previous conventional systemic therapies were associated with lower rates of PASI response. During the study period, 68 patients reported 83 adverse events (AEs) and the most frequent AEs were eczematous lesions. Up to 14.5% patients withdrew treatment due to disease remission combined with inconvenient transportation during the COVID‐19 pandemic at 52 weeks. The rate of psoriasis exacerbation after COVID‐19 infection in patients treated with secukinumab was 24.3% (17/70). This real‐world study confirmed the high effectiveness of secukinumab in Chinese patients with moderate to severe plaque psoriasis, with an acceptable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalPsoriasisAntibodies, Monoclonal, HumanizedHumansProspective StudiesPandemicsTreatment OutcomeSeverity of Illness IndexChina

Stichwörter der Autor:innen

effectivenesspsoriasisreal-worldsafetysecukinumab

Substanzen

secukinumabAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, P. R. China.

ORCID-Profile: Chen Yu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhou, J., Yuan, Y., Liu, Y., Chu, M., Liu, H., Liu, Q., Wang, R., Shao, S., Wang, G., & Yu, C. (2024). Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice. Experimental Dermatology. https://doi.org/10.1111/exd.14890

Vancouver

Zhou J, Yuan Y, Liu Y, Chu M, Liu H, Liu Q, et al. Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice. Experimental Dermatology. 2024. doi:10.1111/exd.14890

BibTeX
@article{Zhou2024,
  author = {Zhou, Jian and Yuan, Yuan and Liu, Yanhua and Chu, Mengyang and Liu, Huan and Liu, Qian and Wang, Rui and Shao, Shuai and Wang, Gang and Yu, Chen},
  title = {Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice},
  journal = {Experimental Dermatology},
  year = {2024},
  doi = {10.1111/exd.14890}
}
Kostenlos starten →